Dostinex

DRUG3 trials

Sponsors

Region Midtjylland, Par Pharmaceutical, Inc.

Conditions

MigraineTo Determine Bioequivalence Under Fasting ConditionsTo Determine Bioequivalence Under Fed Conditions

Phase 1

Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fed Conditions

CompletedNCT00652873

Par Pharmaceutical, Inc.To Determine Bioequivalence Under Fed Conditions

Start: 2001-07-31End: 2001-12-31Updated: 2017-09-26

Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions

CompletedNCT00653055

Par Pharmaceutical, Inc.To Determine Bioequivalence Under Fasting Conditions

Start: 2001-08-31End: 2001-12-31Updated: 2008-04-04

Phase 3

Prevention and Treatment of Episodic migraine by Cabergoline Therapy (PROTECT) A randomized, placebo-controlled, double-blind, investigator-initiated trial

RecruitingCTIS2025-522323-10-00

Region MidtjyllandMigraine

Start: 2025-11-12Target: 150Updated: 2025-12-09